National Cancer Institute
Office of Technology and Industrial Relations

Contact Us  |  Site Map  |   



Skip Navigation


About OTIR Programs Funding Related Research Resources News & Events


Skip Navigation


About OTIR Programs Funding Related Research Resources News & Events


Highlights: What's New

OTIR Programs
PROTEOMICS: 9.27.06 NCI Creates Network of Clinical Proteomic Technology Centers for Cancer Research

PROTEOMICS: 4.24.06 FHCRC releases updated CPAS software for computational proteomics analysis

NCI Related Initiatives
NCI: 03.09.07
2007 NIH Director's New Innovator Award Program (DP2)
Receipt Date: May 22, 2007

NANOTECH: 12.27.06
Receipt Dates: February 20, June 20, October 22, 2007

TCGA: 11.20.06
NHGRI Funds Large-Scale Sequencing Centers

CGEMS: 10.19.06
NCI Releases Preliminary Data on Genetic Susceptibility for Prostate Cancer

The NCI Office of Technology and Industrial Relations (OTIR) is committed to accelerating the progress of cancer research through its technology-driven initiatives, collaboration with other government programs, and engagement with the private sector in the areas of nanotechnology, proteomics, cancer genomics, and biospecimen resources. By placing a heavy emphasis on advanced technology development, the NCI is accelerating the creation and use of tools that are already facilitating the translation of basic knowledge into clinical advances to benefit patients with a new generation of molecularly-based diagnostics and therapeutics.

Alliance for Nanotechnology in Cancer: The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized five-year initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.


Clinical Proteomic Technologies Initiative: The objective of the Clinical Proteomic Technologies Initiative (CPTI) is to build the foundation of technologies, data, reagents and standards, analysis systems, and infrastructure needed to systematically advance our understanding of protein biology in cancer and accelerate discovery research and clinical applications.


Innovative Molecular Analysis Technologies: The Innovative Molecular Analysis Technologies (IMAT) Program is aimed at the inception, development, integration, and application of novel and emerging technologies in the support of cancer research, treatment, diagnosis, and prevention.


Nanotechnology Characterization Laboratory: The National Cancer Institute, working in concert with the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration (FDA), established the Nanotechnology Characterization Laboratory to perform preclinical efficacy and toxicity testing of nanoparticles.

Skip Navigation
National Cancer InstituteDepartment of Health and Human ServicesNational Institutes of